Clinical trial
Interventional, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Initial Administration of 25 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
NCT03766867 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Interventional, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Initial Administration of 25 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
- Lead sponsor
- H. Lundbeck A/S
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 3, 2018
- Completion date
- August 28, 2019
- Enrollment
- 80 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.